Regeneron and Decibel aren’t just collaborating: They want to create a whole new partnering model
Leonard Schleifer, founder and chief executive of Regeneron CNBC, Getty
A veteran biotech exec like Steve Holtzman has seen just about every kind of big-little company collaboration deal in the book — from both sides of the table. Most biotechs, he tells me in his own blunt fashion, prefer a hands-off approach to partnering with the big groups that comes down to this: “Give me your money and stay out of our hair.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
